



Universiteit
Leiden
The Netherlands

Preclinical and 'near-patient' models for the evaluation of experimental therapy in prostate and bladder cancer

Merbel, A.F. van de

Citation

Merbel, A. F. van de. (2023, September 28). *Preclinical and 'near-patient' models for the evaluation of experimental therapy in prostate and bladder cancer*. Retrieved from <https://hdl.handle.net/1887/3642440>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3642440>

Note: To cite this publication please use the final published version (if applicable).

Preclinical and 'near-patient' models for the evaluation of experimental therapy in prostate and bladder cancer

1. The use of patient-derived tumor models, either alone or combined with other preclinical tumor models, represents a valuable tool in identifying novel therapies for urological cancers (*this thesis*).
2. The antipsychotic drug penfluridol exerts anti-tumor effects and may represent a novel strategy in the treatment of bladder and prostate cancer (*this thesis*).
3. *jin-3* mutant Reoviruses infect, replicate and generate anti-cancer responses in preclinical prostate cancer models and induce the expression of interferon-stimulated genes and inflammatory cytokines (*this thesis*).
4. Screening for E-cadherin (re)induction and inhibition of invasion resulted in the identification of novel drug candidates to reduce cancer cell migration and invasion (*this thesis*).
5. Patient-derived xenograft (PDX) models represent a valuable patient derived tumor model. However, thorough screening of PDX models for EBV-induced lymphoma development and murine stromal overgrowth is of crucial importance (*Wetterauer et al. The prostate (2015) and Taurozzi et al. PLoS One (2017)*).
6. Drug repositioning offers an attractive strategy since it involves the use of de-risked compounds, lower development costs and shorter development timelines than developing completely new drugs (*Pushpakom et al. Nature Reviews Drug Discovery (2019)*).
7. Oncolytic viruses hold great potential to induce anti-tumor effects, override immune evasion and promote anti-tumor immunity. In addition, oncolytic viruses can complement other anti-cancer therapies, including immune-checkpoint inhibition, resulting in better clinical outcome. (*Lee et al. Nature Reviews Urology 2018*).

8. EMT-inhibitors may provide great clinical potential as anti-cancer treatment by reducing invasive behavior, reduce stemness and increase therapy sensitivity. Administering EMT-inhibitors in a close therapeutic window is of crucial importance (*Santamaria et al. Molecular oncology 2017*).
9. It is essential to be aware of the advantages and limitations of a model system (inspired by "A model is a lie that helps you see the truth" by Howard Skipper in *The Emperor of all Maladies*, Siddhartha Mukherjee (2010)).
10. Before you can multiply, you must first learn to divide (*Asian wisdom*).
11. The quote "When you learn a little, you feel like you know a lot. But when you learn a lot, you realize you know very little" (*Jay Shetty, Think Like a Monk (2020)*) also applies to scientific research.
12. Taking breaks to unwind and re-charge is crucial for your well-being and improves productivity (inspired by "Almost everything will work again if you unplug it for a few minutes, including you" *Anne Lamott, Bird by Bird (2020)*).